Software and trial services that help drug companies find existing metabolic medicines to test for dementia and other brain outcomes.
AI-enabled drug discovery and repurposing focused on metabolic/neurologic outcomes
AI models in drug discovery are maturing, semaglutide has been linked to lower predicted dementia risk, and Peter Attia is advocating multifactorial trial designs. Those three trends make this a timely moment to use AI and focused trials to test metabolic drugs for cognitive outcomes.
Projected Score
as a side gig ☆☆☆☆☆ (0/5)
no money or audience ★☆☆☆☆ (1/5)
with both ★★★☆☆ (3/5)
Want this one researched? Commission the full dossier for $15: we research and write it, and you read it first. Then you choose — pay more to keep it exclusive, or do nothing and it goes public on this site. The score above is our forecast for a dossier we haven’t written yet.
The news behind it
- Aug 16, 2026 Hacker News (Algolia): AI in drug discovery – what it is, where we stand and the path forward
- Aug 16, 2026 Hacker News (Algolia): Semaglutide linked to lower predicted dementia risk
- Aug 16, 2026 Peter Attia: Multifactorial trials: taking apart the kitchen sink
